SkinBioTherapeutics Bolsters Board with New Audit Chair and CFO Promotion

SkinBioTherapeutics ( (GB:SBTX) ) just unveiled an update.

SkinBioTherapeutics has strengthened its senior leadership team with the appointment of experienced non-executive director and audit specialist Alyson Levett as a non-executive director and Chair of the Audit Committee, and the promotion of Group Finance Director Emily Bertram to Chief Financial Officer and executive board member, effective 1 January 2026. The board reshuffle, which also sees former director Danielle Bekker step down from the board to remain as an external advisor, is positioned by the company as enhancing financial oversight and governance support at a time when management expects an especially active year ahead, potentially improving investor confidence and operational execution as it pursues its growth and consolidation strategy in the skin health sector.

The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.

Spark’s Take on GB:SBTX Stock

According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Underperform.

The overall stock score is primarily impacted by the company’s financial performance challenges, including unprofitability and negative cash flows. Technical analysis indicates bearish momentum, and valuation concerns are heightened by a negative P/E ratio and lack of dividend yield. These factors collectively suggest caution for potential investors.

To see Spark’s full report on GB:SBTX stock, click here.

More about SkinBioTherapeutics

SkinBioTherapeutics plc is a UK-based life sciences company focused on skin health, built around its proprietary SkinBiotix® platform originating from research at the University of Manchester. The group targets the skin healthcare market through five pillars, with its most advanced activities in cosmetic skincare, via a partnership with Croda using SkinBiotix® as active ingredient Zenakine™, and in gut-skin axis food supplements marketed under the AxisBiotix™ brand for inflammatory skin conditions and sold online and through selected Superdrug stores. The company is also pursuing a consolidation strategy, acquiring complementary skincare and cosmetic businesses to expand distribution, geographic reach and manufacturing capabilities; it has been listed on AIM since 2017 and is headquartered in Newcastle, UK.

Average Trading Volume: 1,202,947

Technical Sentiment Signal: Buy

Current Market Cap: £43.35M

See more insights into SBTX stock on TipRanks’ Stock Analysis page.